Ali Al-Khattawi

Lecturer in Pharmaceutics Aston University

Birmingham

Dr Al-Khattawi's research interests are on the development of innovative particle design and fabrication strategies.

Contact

Aston University
View more experts managed by Aston University

View all Experts

Spotlight

May 22, 2024

2 min

Aston University spin-out wins start-up prize at life sciences and medical technology industry awards show

MESOX, a spin-out from the pharmaceutics group at Aston Pharmacy School, develops drug carrier technology to improve medicine formulations The company won the Start-Up prize at the Medilink Midlands Awards 2024 The prize is awarded to a new company that shows a promising future. A spin-out company from Aston University’s pharmaceutics research group has won a medical technology and life sciences industry award. MESOX, which was founded by Aston University pharmaceutics lecturer Dr Ali Al-Khattawi, won the Medilink Midlands Start-Up Award, which is presented to a newly established company that shows a promising future. The Medilink Midlands Business Awards showcase the best collaborations between industry, academia and the NHS across the Midlands. This year’s ceremony was held at the Athena in Leicester on 9 May. The awards were established by Medilink Midlands, which provides specialist business support to boost the region’s economic output from the life sciences industry. Working alongside the Midlands Engine and other strategic alliances, it helps stimulate additional and value-added growth of the Midlands as a prosperous community for life sciences. With in-depth expertise in particle engineering for drug delivery and pharmaceutical spray drying, MESOX uses IP-protected carriers to improve the bioavailability and efficacy of pharmaceuticals, partnering with pharmaceutical and biotechnology companies to bring challenging therapeutics to market. In its citation, Medilink Midlands described MESOX as “transforming pharmaceutical formulation with its game-changing carrier technologies.” As a winner of a Medilink Midlands award, MESOX will now be entered into the UK National Awards, the ceremony of which takes place on 11 July 2024 in London. Dr Al-Khattawi said: “We are delighted to have won this prestigious award, which highlights the outstanding research and development work being done by the MESOX team and the immense potential of our company to transform the medicine formulation development landscape. Through collaboration with other pharmaceutical companies, clinicians, academic researchers, and by engaging directly with patients to understand their needs, we aim to innovate and advance drug delivery science into life-saving therapeutics. “At MESOX, our ambition is to be a global, research-based pharmaceutical company rooted in the Midlands, dedicated to developing life-saving therapeutics at speed and resource-efficiency. Our ultimate goal is to enable healthier lives for patients worldwide and ensure better global access to essential medicines.”

Apr 15, 2024

2 min

Aston University pharmaceutical spin-out company shortlisted in life sciences industry awards

MESOX is a spin-out from the pharmaceutics group at Aston Pharmacy School The company partners with pharmaceutical and biotechnology companies to bring challenging therapeutics to market It has been shortlisted in the Medilink Midlands Awards 2024. A spin-out company from Aston University’s pharmaceutics research group has been shortlisted for a life sciences industry award. The Medilink Midlands Awards aim to showcase the very best collaborations between industry, academia and the NHS across the Midlands. The company, MESOX, founded by Dr Ali Al-Khattawi, a lecturer in pharmaceutics at Aston Pharmacy School, is competing in the Start-Up category for newly established companies that show a promising future. With in-depth expertise in particle engineering for drug delivery and pharmaceutical spray drying, MESOX uses IP-protected carriers to improve the bioavailability and efficacy of pharmaceuticals, partnering with pharmaceutical and biotechnology companies to bring challenging therapeutics to market. Medilink Midlands provides specialist business support to boost the region’s economic output from the life sciences industry. Working alongside the Midlands Engine and other strategic alliances, it helps stimulate additional and value-added growth of the Midlands as a prosperous community for life sciences. The awards winners will be announced at a ceremony taking place on Thursday 9 May at the Athena in Leicester. To celebrate Medilink Midlands’ 20th year anniversary of delivering business support, one finalist will be announced as the 2024 ‘Winner of all Winners’ and presented with a £5,000 prize for innovation development. Dr Ali Al-Khattawi, founder and CEO of MESOX, said: “We are excited to be nominated as a finalist for this award, which is a testament to the innovative research at Aston University that has led to MESOX and a great way to recognise the efforts of our team. “MESOX is expediting the development of life-saving therapeutics through cutting-edge carrier technologies. Our vision is to be a leading research-based pharmaceutical company in the Midlands one day and we hope this opportunity brings us a step closer to this goal.” Luke Southan, technology transfer manager at Aston University, said: “Aston University’s School of Pharmacy has always been a hotbed of innovation and entrepreneurship. This is most often seen through our many students who end up running their own independent pharmacy stores, but it is also the school that has created the most Aston spinouts. “MESOX is the latest example of this, and it is a company that is on track to be generating significant revenue and region impact over the next five years. This award nomination evidences the potential the company has to offer.”

Media

Social

Biography

Dr Al-Khattawi joined Aston University as a Lecturer in Pharmaceutics in 2016. His research interests are centred on the development of innovative particle design and fabrication strategies that can contribute to the future precision manufacturing of pharmaceutical products.

Ali has expertise in pharmaceutical particle engineering gained throughout several industrially focused projects. His group has expertise in pharmaceutical spray drying for solubility enhancement, control of particle structure, meso and macro-porous carriers for drug delivery as well as other novel particle manufacturing and characterization techniques. They also support the industry on a regular basis through the development of new technical solutions.

Areas of Expertise

Pharamaceuticals

Pharmaceutical Products

Pharmaceutical Particle Engineering

Fabrication Strategies

Accomplishments

International Pharmaceutical Excipients Council (IPEC) Research Excellence Award

2013

Royal Society of Chemistry (RSC) – Process Technology Group Award, Sheffield

2011

Education

Aston University - Aston Pharmacy School

PhD

Pharmaceutics / Drug Delivery

2014

Aston University - Centre for Learning Innovation and Professional Practice (CLIPP)

Postgraduate Teaching Certificate

2013

Kingston University - School of Pharmacy and Chemistry

Pharmaceutical Sciences

2010

Show All +

Articles

Delivery of Poorly Soluble Drugs via Mesoporous Silica: Impact of Drug Overloading on Release and Thermal Profiles

Pharmaceutics

2019

Among the many methods available for solubility enhancement, mesoporous carriers are generating significant industrial interest. Owing to the spatial confinement of drug molecules within the mesopore network, low solubility crystalline drugs can be converted into their amorphous counterparts, which exhibit higher solubility. This work aims to understand the impact of drug overloading, i.e., above theoretical monolayer surface coverage, within mesoporous silica on the release behaviour and the thermal properties of loaded drugs. The study also looks at the inclusion of hypromellose acetate succinate (HPMCAS) to improve amorphisation. Various techniques including DSC, TGA, SEM, assay and dissolution were employed to investigate critical formulation factors of drug-loaded mesoporous silica prepared at drug loads of 100–300% of monolayer surface coverage, i.e., monolayer, double layer and triple layer coverage. A significant improvement in the dissolution of both Felodipine and Furosemide was obtained (96.4% and 96.2%, respectively). However, incomplete drug release was also observed at low drug load in both drugs, possibly due to a reversible adsorption to mesoporous silica. The addition of a polymeric precipitation inhibitor HPMCAS to mesoporous silica did not promote amorphisation. In fact, a partial coating of HPMCAS was observed on the exterior surface of mesoporous silica particles, which resulted in slower release for both drugs.

Quality by Design (QbD) based process optimisation to develop functionalised particles with modified release properties using novel dry particle coating technique

PLoS ONE

2018

Quality by Design (QbD), a current trend employed to develop and optimise various critical pharmaceutical processes, is a systematic approach based on the ethos that quality should be designed into the product itself, not just end tested after manufacture. The present work details a step-wise application of QbD principles to optimise process parameters for production of particles with modified functionalities, using dry particle coating technology. Initial risk assessment identified speed, air pressure, processing time and batch size (independent factors) as having high-to-medium impact on the dry coating process. A design of experiments (DOE) using MODDE software employed a D-optimal design to determine the effect of variations in these factors on identified responses (content uniformity, dissolution rate, particle size and intensity of Fourier transform infrared (FTIR) C = O spectrum). Results showed that batch size had the most significant effect on dissolution rate, particle size and FTIR; with an increase in batch size enhancing dissolution rate, decreasing particle size (depicting absence of coated particles) and increasing the FTIR intensity. While content uniformity was affected by various interaction terms, with speed and batch size having the highest negative effect. Optimal design space for producing functionalised particles with optimal properties required maximum air pressure (40psi), low batch size (6g), speed between 850 to 1500 rpm and processing times between 15 to 60 minutes. The validity and predictive ability of the revised model demonstrated reliability for all experiments. Overall, QbD was demonstrated to provide an expedient and cost effective tool for developing and optimising processes in the pharmaceutical industry.

Understanding the compaction behaviour of Low-substituted HPC: Macro, micro and nano-metric evaluations

Pharmaceutical Development and Technology

2017

The fast development in materials science has resulted in the emergence of new pharmaceutical materials with superior physical and mechanical properties. Low-substituted hydroxypropyl cellulose is an ether derivative of cellulose and is praised for its multi-functionality as a binder, disintegrant, film coating agent and as a suitable material for medical dressings. Nevertheless, very little is known about the compaction behaviour of this polymer. The aim of the current study was to evaluate the compaction and disintegration behaviour of four grades of L-HPC namely; LH32, LH21, LH11 and LHB1. The macrometric properties of the four powders were studied and the compaction behaviour was evaluated using the out-of-die method. LH11 and LH22 showed poor flow properties as the powders were dominated by fibrous particles with high aspect ratios, which reduced the powder flow. LH32 showed a weak compressibility profile and demonstrated a large elastic region, making it harder for this polymer to deform plastically. These findings are supported by AFM which revealed the high roughness of LH32 powder (100.09±18.84 nm), resulting in small area of contact, but promoting mechanical interlocking. On the contrary, LH21 and LH11 powders had smooth surfaces which enabled larger contact area and higher adhesion forces of 21.01±11.35 nN and 9.50±5.78 nN respectively. This promoted bond formation during compression as LH21 and LH11 powders had low strength yield.